Cancer Research and Treatment

Original Article

Hematologic malignancy

Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma: Do Young Kim, Jehyun Nam, Joo-seop Chung, Sang-Woo Kim, Ho-Jin Shin; Cancer Res Treat. 2022;54(1):301-313. Published online April 27, 2021; DOI: https://doi.org/10.4143/crt.2020.1371

Purpose
There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective phosphodiesterase-4 inhibitor used for treating chronic obstructive pulmonary disease, is effective against B-cell malignancy via phosphoinositide 3-kinase (PI3K)–activity suppression. We analyzed the effects of roflumilast combined with ESHAP (etoposide, cisplatin, methylprednisolone, and cytarabine) chemotherapy in experimental and clinical settings.
Materials and Methods
An in vitro study using lymphoma cell lines and a pilot study on relapsed/refractory DLBCL patients were conducted to investigate the effects and mechanism of the combination of roflumilast and chemotherapy. The complete response (CR), overall response rate (ORR), and 1-year progression-free survival (PFS) were analyzed.
Results
We found that roflumilast is efficient when combined with other chemotherapy drugs, especially cytarabine. Synergistic effects between these two drugs influence the translation of mammalian target of rapamycin and myeloid cell leukemia 1, resulting in apoptosis and inhibition of B-cell lymphoma proliferation. In clinical setting, the roflumilast group showed better rates of CR (46.2% vs. 34.6%), ORR (76.9% vs. 53.8%), and 1-year PFS (50.0% vs. 25.9%) compared with the control group, though not statistically significant. The roflumilast group showed a higher incidence of asthenia and gastrointestinal adverse events. However, grade 3 or 4 adverse events were similar in both groups.
Conclusion
We found that roflumilast, when combined with ESHAP chemotherapy, for relapsed/refractory DLBCL was clinically active and well tolerated. This combined treatment was able to suppress PI3K activity, which is correlated with the degree of clinical response.

Citations

Citations to this article as recorded by

Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic Outgrowth
Jessica L. Christenson, Nicole S. Spoelstra, Michelle M. Williams, Linda L. Logan, Kathleen I. O’Neill, David J. Orlicky, Nolan T. Baker, Jennifer A. Wagner, Alyse W. Staley, Adrie Van Bokhoven, Andrew Goodspeed, Li-Wei Kuo, Lyndsey S. Crump, Jennifer R.
Cancer Research Communications.2026; 6(4): 750. CrossRef
Roflumilast attenuates doxorubicin and cyclophosphamide combination-induced chemobrain in rats through modulation of NLRP3/ASC/caspase-1/GSDMD axis
Georgette Eskander, Sherihan G. Abdelhamid, Sara A. Wahdan, Sara M. Radwan
Life Sciences.2025; 362: 123378. CrossRef
The multifaceted role of phosphodiesterase 4 in tumor: from tumorigenesis to immunotherapy
Huili-li Ren, Shao-hui Zhang, Pei-yuan Li
Frontiers in Immunology.2025;[Epub] CrossRef
Roflumilast tópico y oral en dermatología. Una revisión narrativa
M. Mansilla-Polo, E. Gimeno, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas.2024; 115(3): 265. CrossRef
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Hongying Zhang, Yongliang Liu, Jieya Liu, Jinzhu Chen, Jiao Wang, Hui Hua, Yangfu Jiang
Journal of Hematology & Oncology.2024;[Epub] CrossRef
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
M. Mansilla-Polo, E. Gimeno, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas.2024; 115(3): T265. CrossRef
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL
Qinqiao Lai, Yan Zhao, Haiqing Yan, Hongling Peng
Leukemia Research.2023; 135: 107406. CrossRef

9,321 View
223 Download
6 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search